In this study,ciglitazone was effective in reducing the growth of thyroid cancer cells thatexpressed PPARγ, but had no effect in reducing growth in athyroid cancer cell line that do not express PPARγ [10].After introduction of wild-type PPARγ into the PPARγ-deficient cells, these cells became responsiveto ciglitazone. The gene discussed is PPARG; the disease is thyroid cancer.